Phase 1 Environmental Site Assessment Consultants | Pharmaceutical | SLP Thailand
Phase 1 Environmental Site Assessment for a Vaccine Manufacturing Facility in Chachoengsao
SLP Environmental conducted a Phase 1 Environmental Site Assessment (ESA) to ASTM-21 standards for a global pharmaceutical company at a vaccine manufacturing facility in Chachoengsao, Thailand. The study assessed potential soil and groundwater contamination liabilities associated with the property, which included production, quality control laboratory and warehousing operations. Site inspections, interviews and historical land-use research informed a conceptual site model, helping identify potential contamination pathways, sensitive environmental receptors and Recognised Environmental Conditions.
Operations at the subject property comprised of the vaccine manufacturing as well as general administrative, QC laboratory and warehousing functions.
The scope of works comprised of a site and environs reconnaissance, interviews with key informants and desk study to assess the landuse history of the area and the physical and biological environmental setting.
These studies culminated in the determination of the environmental sensitivity of the project site area, and an assessment of the contaminative potential of neighboring properties.
SLP constructed a conceptual site model (CSM) for the subject property in order to examine potential linkages between sources of contamination and sensitive environmental receptors (e.g. soils, surface water groundwater and ecology), which aided in the determination as to whether any Recognised Environmental Conditions and/or De Minimis conditions (as defined under ASTM 1527) were associated with the subject property.